Prediction of Fetal Growth Restriction Using Combined Fetal Biometry and Maternal Serum( Inhibin A) in Pregnant Women with Type 1 Diabetes.

Abstract

Prediction of Fetal Growth Restriction using Combined Fetal Biometry and Maternal Serum [Inhibin A] in Pregnant Women with Type 1 DiabetesAbstractBackground: FGR is a major determinant of perinatal and childhood morbidity and mortality and is associated with the risk of chronic diseases in later life.Objective: to assess the diagnostic value of early detection of fetal growth restriction using combined fetal biometry and maternal serum biomarker inhibin A in type 1 diabetic patients.Patients and Methods: A prospective study on 100 diabetic pregnant women. Maternal Serum Inhibin A, Hemoglobin AIC, fasting glucose serum levels, all done for each patient once in second trimester. Serial fetal ultrasound biometry done as one assessment in second trimester and two assessments in third trimester. Ultrasonic markers for fetal growth restriction were performed. Follow-up was done for 3 antenatal care visits.Results: The IUGR was [66%] and non-IUGR was [34%]. Mean serum inhibin A level in IUGR cases 673.83± 470.43, mean serum inhibin A in NON- IUGR cases 102.06 ± 106.29) P value